

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The efficacy of synbiotic supplements containing *Bacillus coagulans* and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome

#### Protocol summary

##### Study aim

To investigate the efficacy of synbiotic supplements containing *Bacillus coagulans* and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome.

##### Design

Randomized Clinical Trial double blind

##### Settings and conduct

In this study, patients with irritable bowel syndrome referring to Taleghani Hospital, if they wish to participate in the study informed consent of them will be taken. Patients were randomized to receive a synbiotic containing *Bacillus coagulans* plus low FODMAP diet or low FODMAP diet (and placebo) for 8 weeks. Before and after the intervention blood and fecal samples will be collected and scores will be evaluated for the evaluation of IBS symptoms.

##### Participants/Inclusion and exclusion criteria

1) 18-65 years 2) Patients with irritable bowel syndrome, according to gastroenterologist diagnosed according to the ROME-IV criteria 3) lack of any organic intestinal disease (diagnosed by last 5 years ago colonoscopy) and intestinal infections (diagnosed by stool culture). 4) No medical history of chronic gastrointestinal and colorectal disease. Absence of any major bowel surgery 5) Absence of regular use of laxatives or antidiarrheal drugs

##### Intervention groups

Intervention group: will receive one synbiotic capsule containing *Bacillus coagulans* (0.1 g) and inulin (0.9 g) per day plus low FODMAP diet for 8 weeks. Control: will receive low FODMAP diet and placebo for 8 weeks

##### Main outcome variables

Abdominal pain intensity, Abdominal pain frequency, Abdominal distension, Satisfaction with bowel habits, Interference with community function, Defecation

frequency, Defecation consistency, Patient-rated Severity score, serum level of IL-6 and INF- $\gamma$

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20100524004010N27**

Registration date: **2018-12-13, 1397/09/22**

Registration timing: **retrospective**

Last update: **2018-12-13, 1397/09/22**

Update count: **0**

##### Registration date

2018-12-13, 1397/09/22

##### Registrant information

##### Name

Azita Hekmatdoost

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences,  
National Institute of Nutrition Research

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2293 0824

##### Email address

hekmat@sina.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-09-22, 1396/06/31

##### Expected recruitment end date

2018-10-22, 1397/07/30

**Actual recruitment start date**  
empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
The efficacy of synbiotic supplements containing Bacillus coagulans and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome

**Public title**  
Effect of Bacillus coagulans and inulin compared with low FODMAP diet in treatment of IBS

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
18-65 years Patients with irritable bowel syndrome, according to gastroenterologist diagnosed according to the ROME- IV criteria (1.Improvement with defecation  
2.Onset associated with a change in stool frequency  
3.Onset associated with a change in stool form (appearance) At least three days a month, three months a year and no pathological findings in the clinical investigating) lack of any organic intestinal disease(diagnosed by last 5 years ago colonoscopy) and intestinal infections(diagnosed by stool culture). No medical history of chronic gastrointestinal and colorectal disease Absence of any major bowel surgery Absence of regular use of laxatives or antidiarrheal drugs No chronic use of antibiotics, corticosteroids and immunosuppressants No usage of drugs that modifying the digestive motility such as metoclopramide, cisapride, diphenoxylate,... No usage of drugs that increased bleeding of intestinal mucosa such as aspirin, warfarin, heparin,... No history of breast cancer in patient or in first-degree relatives of a person Absence of severe mental or behavioral disorder Absence of nicotine and its derivatives use in last 6 months No usage of NSAIDs and aspirin in last week(influence on gut permeability)  
**Exclusion criteria:**  
Life threatening symptoms Death Not agree to continue the study

**Age**  
From **18 years** old to **65 years** old

**Gender**  
Both

**Phase**  
N/A

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **50**  
Actual sample size reached: **50**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**

The method use in this study to create a randomization process is simple randomization, so we utilize random number table. Beginning of the study, each person is randomly assigned to one of the 2 study groups according to the randomized distribution table.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description**

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sci

**Street address**

West arghavan, Sanaat square, Farahzadi boulevard, Shahrake gharb

**City**

Tehran

**Province**

Tehran

**Postal code**

193954741

**Approval date**

2017-12-31, 1396/10/10

**Ethics committee reference number**

IR.SBMU.nnftri.Rec.1396.206

**Health conditions studied**

**1**

**Description of health condition studied**

Irritable Bowel Syndrom

**ICD-10 code**

K58

**ICD-10 code description**

Irritable bowel syndrome

**Primary outcomes**

**1**

**Description**

Abdominal pain intensity

**Timepoint**

Beginning and end of study

**Method of measurement**

Questionnaire

## 2

### **Description**

Abdominal pain frequency

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## 3

### **Description**

Abdominal distension

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## 4

### **Description**

Satisfaction with bowel habits

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## 5

### **Description**

Interference with community function

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## 6

### **Description**

Defecation frequency

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## 7

### **Description**

Defecation consistency

### **Timepoint**

Beginning and end of study

### **Method of measurement**

Questionnaire

## **Secondary outcomes**

## 1

### **Description**

Patient-rated Severity score

### **Timepoint**

Beginning and end of the study

### **Method of measurement**

Questionnaire

## 2

### **Description**

IBS-SSS

### **Timepoint**

Beginning and end of the study

### **Method of measurement**

Questionnaire

## 3

### **Description**

IL-6

### **Timepoint**

Beginning and end of the study

### **Method of measurement**

Enzymatic method using a kit

## 4

### **Description**

INF- $\gamma$

### **Timepoint**

Beginning and end of the study

### **Method of measurement**

Enzymatic method using a kit

## **Intervention groups**

## 1

### **Description**

Intervention group: will receive one synbiotic capsule containing *Bacillus coagulans*(0.1) g and inulin(0.9 g) per day plus low FODMAP diet for 8 weeks

### **Category**

Treatment - Other

## 2

### **Description**

Control group: will receive low FODMAP diet and placebo (starch) for 8 weeks

### **Category**

Placebo

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Taleqani Hospital

#### **Full name of responsible person**

Amir Sadeghi

#### **Street address**

Arabi Ave, Daneshjoo Blvd, Velenjak

#### **City**

Tehran

#### **Province**

Tehran  
**Postal code**  
1985711151  
**Phone**  
+98 21 2243 2560  
**Email**  
taleghanihospital@sbmu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Afshin Zarghi  
**Street address**  
West arghavan, Sanaat square, Farahzadi boulevard,  
Shahrake gharb  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
00  
**Phone**  
+98 21 23871  
**Email**  
A\_hekmat2000@yahoo.com  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Shahid Beheshti University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Azita Hekmatdoost  
**Position**  
Associate professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Nutrition

#### Street address

West arghavan, Sanaat square, Farahzadi boulevard,  
Qods Town

#### City

Tehran

#### Province

Tehran

#### Postal code

00

#### Phone

+98 912 306 5084

#### Email

A\_hekmat2000@yahoo.com

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Azita Hekmatdoost  
**Position**  
Associate professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
West arghavan, Sanaat square, Farahzadi boulevard,  
Qods Town  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
00  
**Phone**  
+98 912 306 5084  
**Email**  
A\_hekmat2000@yahoo.com

## Person responsible for updating data

#### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Khadijeh Abhari  
**Position**  
Postdoctoral Fellowship  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Food safety and Health  
**Street address**  
No. 7, West Arghavan Ave., Farahzadi Blvd., Qods  
Town,  
**City**  
Tehran  
**Province**  
Tehran

**Postal code**

00

**Phone**

+98 917 303 2478

**Email**

m65abhari@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

Because the participant's informations should remain confidential.

**Study Protocol**

Undecided - It is not yet known if there will be a plan to

make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available